Bone mineral density in adult survivors of childhood acute leukemia: Impact of hematopoietic stem cell transplantation and other treatment modalities

Blood

Volumn 118, Issue 6, 2011, Pages 1481-1489

  Le Meignen, Marion ^a   Auquier, Pascal ^b   Barlogis, Vincent ^c   Sirvent, Nicolas ^d   Contet, Audrey ^e   Simeoni, Marie Claude ^b   Galambrun, Claire ^c   Poirée, Marilyne ^a   Chastagner, Pascal ^e   Play, Barbara ^c   Villes, Virginie ^b   Berbis, Julie ^b   Chambost, Hervé ^c   Bordigoni, Pierre ^e   Michel, Gérard ^c  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b HÔPITAL NORD   (France)

^c TIMONE HOSPITAL   (France)

^d HÔPITAL ARNAUD DE VILLENEUVE   (France)

^e HÔPITAL D ENFANTS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; PREDNISONE;

ACUTE LEUKEMIA; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE DENSITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CANCER SURVIVOR; CHILDHOOD CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FEMUR; GROWTH HORMONE DEFICIENCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOGONADISM; LUMBAR SPINE; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS;

EID: 80051676495     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-01-332866     Document Type: Article

References (50)

1. Halton JM, Atkinson SA, Fraher L, et al. Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia. J Bone Miner Res. 1996;11(11):1774-1783. (Pubitemid 26367689)
2. Henderson RC, Madsen CD, Davis C, Gold SH. Longitudinal evaluation of bone mineral density in children receiving chemotherapy. J Pediatr Hematol Oncol. 1998;20(4):322-326. (Pubitemid 28483339)
3. Arikosky P, Komulainen J, Riikonen P, Voutilainen R, Knip M, Kröger H. Alterations in bone turnover and impaired development of bone mineral density in newly diagnosed children with cancer: a 1-year prospective study. J Clin Endocrinol Metab. 1999;84(9):3174-3181. (Pubitemid 30646940)
4. Van der Sluis JM, van den Heuvel-Eibrink MM, Hählen K, Krenning EP, de Muinck Keizer- Schrama SM. Altered bone mineral density and body composition and increased fracture risk in childhood acute lymphoblastic leukemia. J Pediatr. 2002;141(2):204-210.
5. Lequin MH, van de Sluis IM, Van Rijn RR, et al. Bone mineral assessment with tibial ultrasonometry and dual-energy X-ray absorptiometry in long-term survivors of acute lymphoblastic leukemia in childhood. J Clin Densitom. 2002;5(2):167-173.
6. Mandel K, Atkinson S, Barr RD, Pencharz P. Skeletal morbidity in childhood acute lymphoblastic leukemia. J Clin Oncol. 2004;22(7):1215-1221. (Pubitemid 41079834)
7. Van Beek RD, de Muinck Keizer-Schrama SM, Hakvoort-Kammel FG, et al. No difference between prednisolone and dexamethasone treatment in bone mineral density and growth in long term survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2006;46(1):88-93.
8. van der Sluis IM, van den Heuvel-Eibrink MM, Hählen K, Krenning EP, de Muinck Keizer-Schrama SM. Bone mineral density, body composition, and height in long-term survivors of acute lymphoblastic leukemia in childhood. Med Pediatr Oncol. 2000;35(4):415-420.
9. Kadan-Lottick N, Marshall JA, Baron AE, Krebs NF, Hambidge KM, Albano E. Normal bone mineral density after treatment for childhood acute lymphoblastic leukemia diagnosed between 1991 and 1998. J Pediatr. 2001;138(6):898-904. (Pubitemid 32545594)
10. Henderson RC, Madsen CD, Davis C, Gold SH. Bone density in survivors of childhood malignancies. J Pediatr Hematol Oncol. 1996;18(4):367-371. (Pubitemid 26359253)
11. Nysom K, Holm K, Michaelsen KF, Hertz H, Muller J, Molgaard C. Bone mass after treatment for acute lymphoblastic leukemia in childhood. J Clin Oncol. 1998;16(12):3752-3760. (Pubitemid 29001526)
12. Hesseling PB, Hough SF, Nel ED, Van Riet FA, Beneke T, Wessels G. Bone mineral density in long-term survivors of childhood cancer. Int J Cancer Suppl. 1998;11:44-47.
13. Arikosky P, Komulainen J, Voutilainen R, et al. Reduced bone mineral density in long-term survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 1998;20(3):234-240. (Pubitemid 28280900)
14. Hoorweg-Nijman JJ, Kardos G, Roos JC, et al. Bone mineral density and markers of bone turnover in young adult survivors of childhood lymphoblastic leukaemia. Clin Endocrinol (Oxf). 1999;50(2):237-244. (Pubitemid 29100012)
15. Brennan BMD, Rahim A, Adams JA, Eden OB, Shalet SM. Reduced bone mineral density in young adults following cure of acute lymphoblastic leukemia in childhood. Br J Cancer. 1999;79(11-12):1859-1863. (Pubitemid 29132316)
16. Warner JT, Evans WD, Webb DK, Bell W, Gregory JW. Relative osteopenia after treatment for acute lymphoblastic leukemia. Pediatr Res. 1999;45(4 Pt 1):544-551. (Pubitemid 29162735)
17. Kaste SC, Jones Wallace D, Rose SR, et al. Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: frequency of occurrence and risk factors for their development. Leukemia. 2001;15(5):728-734. (Pubitemid 32492695)
18. Tillmann V, Darlington AS, Eiser C, Bishop NJ, Davies HA. Male sex and low physical activity are associated with reduced spine bone mineral density in survivors of childhood acute lymphoblastic leukemia. J Bone Miner Res. 2002;17(6):1073-1080. (Pubitemid 34535146)
19. Wasilewski-Masker K, Kaste SC, Hudson MM, Esiashvili N, Mattano LA, Meacham LR. Bone mineral density deficits in survivors of childhood cancer: long-term follow-up guidelines and review of the literature. Pediatrics. 2008;121(3):e705-e713.
20. Michel G, Bordigoni P, Simeoni MC, et al. Health status and quality of life in long-term survivors of childhood leukaemia: the impact of haematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;40(9):897-904. (Pubitemid 350020326)
21. Lewiecki EM, Gordon CM, Baim S, et al. International Society for Clinical Densitometry 2007 official adult and pediatric positions. Bone. 2008;43(6):1115-1121.
22. Schaison G, Sommelet D, Bancillon A, et al. Treatment of acute lymphoblastic leukemia French protocol Fralle 83-87. Leukemia. 1992;6(Suppl 2):148-152.
23. Perel Y, Auvrignon A, Leblanc T, et al. Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit-multicenter studies of the French LAME (Leucemie Aigue Myeloblastique Enfant) Cooperative Group. Leukemia. 2005;19(12):2082-2089. (Pubitemid 41741600)
24. Oudot C, Auclerc MF, Levy V, et al. Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study. J Clin Oncol. 2008;26(9):1496-1503.
25. Uyttebroeck A, Suciu S, Laureys G, et al: Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial. Eur J Cancer. 2008;44(6):840-846.
26. Johnston CC Jr, Slemenda CW. Determinants of peak bone mass. Osteoporis Int. 1993;3(Suppl 1):54-55. (Pubitemid 23099889)
27. Sabatier JP, Guaydier-Souquières G, Laroche D, et al. Bone mineral acquisition during adolescence and early adulthood: a study in 574 healthy females 10-24 years of age. Osteoporos Int. 1996;6(1):141-148. (Pubitemid 26099837)
28. Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement Online. 2000;17(1):1-36.
29. Gilsanz V, Carlson ME, Roe TF, Ortega JA. Osteoporosis after cranial irradiation for acute lymphoblastic leukemia. J Pediatr. 1990;117(2 Pt 1):238-244. (Pubitemid 20238536)
30. Kaufman JM, Taelman P, Vermeulen A, Vandeweghe M. Bone mineral status in Growthhormone deficient males with isolated and multiple pituitary deficiencies of childhood onset. J Clin Endocrinol Metab. 1992;74(1):118-123.
31. Hyer SL, Rodin DA, Tobias JH, Leyper A, Nussey SS. Growth hormone deficiency during puberty reduces adult bone mineral density. Arch Dis Child. 1992;67(12):1472-1474. (Pubitemid 23008273)
32. Holmes SJ, Shalet SM. Role of growth hormone and sex steroids in achieving and maintaining normal bone mass. Horm Res. 1996;45(1-2):86-93. (Pubitemid 26034769)
33. Nussey SS, Hyer SL, Brada M, Leiper AD, Pazianas M. Bone mineralization after treatment of growth hormone deficiency in survivors of childhood malignancy. Acta Pediatr Suppl. 1994;399:9-14.
34. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy, Osteop Int. 2007;18(10):1319-1328. (Pubitemid 47389469)
35. Mazziotti G, Canalis E, Giustina A. Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med. 2010;123(10):877-884.
36. Ragab AH, Fresh RS, Vietti TJ. Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission. Cancer. 1970;25(3):580-585.
37. Stanisavljevic S, Babcock AL. Fractures in children treated with methotrexate for leukemia. Clin Orthop Relat Res. 1977;(125):139-144.
38. Tauchmanovà L, Colao A, Lombardi G, Rotoli B, Selleri C. Bone loss and its management in longterm survivors from allogeneic stem cell transplantation. J Clin Endocrinol Metab. 2007;92(12):4536-4545.
39. Bhatia S, Ramsay NKC, Weisdorf D, Griffiths H, Robison LL. Bone mineral density in patients undergoing bone marrow transplantation for myeloid malignancies. Bone Marrow Transplant. 1998;22(1):87-90. (Pubitemid 28330541)
40. Nysom K, Holm K, Fleischer Michaelsen K, et al. Bone mass after allogenic BMT for childhood leukemia or lymphoma. Bone Marrow Transplant. 2000;25(2):191-196. (Pubitemid 30087990)
41. Daniels MW, Wilson DM, Paguntalan HG, et al. Bone mineral density in pediatric transplant recipients. Transplantation. 2003;76(4):673-678. (Pubitemid 37072001)
42. Kaste SC, Shidler TJ, Tong X, et al. Bone mineral density and osteonecrosis in survivors of childhood allogenic bone marrow transplantation. Bone Marrow Transplant. 2004;33(4):435-441. (Pubitemid 38313094)
43. McClune BL, Polgreen LE, Burmeister LA, et al. Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients. Bone Marrow Transplant. 2011;46(1):1-9.
44. Tauchmanova L, Serio B, Del Puente A, et al. Long-lasting bone damage detected by dual energy X-ray absorbtiometry, phalangeal osteosonogrammetry and in vitro growth of marrow stroma cells after allogenic stem cell transplantation. J Clin Endocrinol Metab. 2002;87(11):5058-5065. (Pubitemid 35316346)
45. Kananen K, Volin L, Tahtela R, Laitenen K, Ruutu T, Valimaki MJ. Recovery of bone mass and normalization of bone turnover in long-term survivors of allogenic bone marrow transplantation. Bone Marrow Transplant. 2002;29(1):33-39. (Pubitemid 34126496)
46. Schulte CMS, Beelen DW. Bone loss following hematopoietic stem cell transplantation, a long term follow-up. Blood. 2004;103(10):3635-3643. (Pubitemid 38596275)
47. Ebeling PR, Thomas DM, Erbas B, Hopper JL, Szer J, Grigg AP. Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation. J Bone Miner Res. 1999;14(3):342-350. (Pubitemid 29106711)
48. Valimaki MJ, Kinnunen K, Volin L, et al. A prospective study of bone loss and turnover after allogenic bone marrow transplantation: effect of calcium supplementation with or without calcitonin. Bone Marrow Transplant. 1999;23(4):355-361. (Pubitemid 29105959)
49. Stern JM, Sullivan KM, Ott SM, Seidel K, et al. Bone density loss after allogeneic stem cell transplantation: a prospective study. Biol Blood Marrow Transplant. 2001;7(5):257-264. (Pubitemid 32591296)
50. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. The study of Osteoporotic Fractures Research Group. Lancet. 1993;341(8837):72-75. (Pubitemid 23028113)